ObvioHealth Appoints Two New Company Executives
New hires expected to reinforce the company's clinical and digital trial expertise.
ObvioHealth, a virtual research organization (VRO), has announced the appointmet of John Cassidy as chief financial officer and Florence Mowlem as VP of science. Previously, Cassidy served as the global head of product and commercial for eClinical at LabCorp while Mowlem joins ObvioHealth after working for Medable, where she led a team driving the implementation of electronic clinical outcomes assessments (eCOAs).
"ObvioHealth has a unique model blending clinical expertise with a robust platform to deliver stronger evidence and accelerated timelines for drug development," said Cassidy, in a company press release. "It is the perfect time to join this experienced team to help bring the business to a new level of growth."
Reference: ObvioHealth Strengthens Leadership Team with Key Industry Appointments. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/obviohealth-strengthens-leadership-team-with-key-industry-appointments-301956006.html
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
